Skip to main content
Fig. 6 | Acta Neuropathologica Communications

Fig. 6

From: LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons

Fig. 6

Neither G2019S LRRK2 expression nor LRRK2 inhibition alters α-synuclein pathology in midbrain neurons. a Primary midbrain/striatum cultures from NTG or G2019S pups were transduced with α-synuclein PFFs and allowed to age a further 14 days prior to fixation and staining for pS129 α-synuclein (magenta) and TH (gray). The neurons were additionally treated with 30 nM LRRK2 inhibitors PF-475, PF-360, or MLi-2 2 days prior to transduction and fed with media containing inhibitors each week thereafter. b Quantification of α-synuclein pathology in TH+ neurons shows no effect of G2019S LRRK2 expression or LRRK2 inhibitor treatments by 2-way ANOVA (**p < 0.01, ***p < 0.001 for PBS- compared to PFF-treated neurons by Dunnett’s multiple comparison test). c The number of TH+ neurons showed no significant response to treatment by Kruskal-Wallis test followed by Dunn’s multiple comparison test. (N = 6–9 biological replicates). Means + s.e.m.; all values are normalized to NTG neurons treated with α-synuclein LB material and DMSO. Scale bars = 50 μm

Back to article page
\